Table 4.
Major Phase III Trials of Neoadjuvant Chemotherapy for Gastric Cancer.
| Trial name | Published
year |
No. of
patients |
Eligible
patients |
Treatment groups | R0 resection
rate (%) |
OS
(%) |
P-value |
|---|---|---|---|---|---|---|---|
| MAGIC (48) | 2006 | 503 | cStage II-III | Surgery alone
ECF (Peri) |
66.4
69.3 |
5-year: 23.0
5-year: 36.3 |
0.009 |
| FLOT4 (49), (50) | 2016, 2017 | 716 | cStage IB-III | ECF/ECX (Peri)
FLOT (Peri) |
77
84 |
3-year: 48
3-year: 57 |
0.012 |
| JCOG0501 (52) | 2018 | 300 | Type 3 (≥8cm)
or Type 4 |
CS (Pre) + S-1 (Post)
S-1 (Post) |
74.2
65.7 |
3-year: 62.4
3-year: 60.9 |
0.284* |
* one-sided p-value.
Abbreviations: OS, overall survival; ECF, epirubicin plus cisplatin plus fluorouracil; ECX, epirubicin plus cisplatin plus capecitabine; FLOT, fluorouracil plus leucovorin plus oxaliplatin plus docetaxel; CS, cisplatin plus S-1; Peri, perioperative; Pre, preoperative; Post, postoperative.